![Zealand Pharma præse](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand Pharma præsenterer nye data fra prækliniske studier med ny GLP-1-gastrin dobbeltagonist, som viser signifikant forøgelse af beta-cellemassen i bugspytkirtlen og en forbedret blodsukkerkontrol
October 04, 2012 05:10 ET
|
Zealand Pharma A/S
København, 2012-10-04 11:10 CEST (GLOBE NEWSWIRE) --
Pressemeddelelse
No. 8/2012
- Data på ZP3022, en ny GLP-1-gastrin dobbeltagonist, blev fremlagt af selskabet i...
![Zealand Pharma prese](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand Pharma presents new preclinical data on novel GLP-1-gastrin dual agonist showing significant increase in pancreatic beta-cell mass and improvement of glycemic control
October 04, 2012 05:10 ET
|
Zealand Pharma A/S
Copenhagen, 2012-10-04 11:10 CEST (GLOBE NEWSWIRE) --
Press Release
No. 8/2012
- Data on ZP3022, a novel GLP-1-gastrin dual agonist, revealed by the company in presentations at the...
![Zealand Pharma infor](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand Pharma informs that Sanofi presents data at EASD to support the potential of Lyxumia®1 (lixisenatide) in combination with basal insulin plus oral anti-diabetics for improved glycemic control in Type 2 diabetes
October 02, 2012 06:13 ET
|
Zealand Pharma A/S
Copenhagen, 2012-10-02 12:13 CEST (GLOBE NEWSWIRE) --
Press Release
No. 7/2012
Clinical study results show that the mechanism of action of lixisenatide as a once-daily GLP-1 agonist...
![Zealand Pharma medde](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand Pharma meddeler, at Sanofi på EASD præsenterer data, som understøtter potentialet for Lyxumia®1 (lixisenatid) i kombination med basal insulin plus oral diabetesmedicin til forbedret blodsukkerkontrol i type 2-diabetes
October 02, 2012 06:13 ET
|
Zealand Pharma A/S
København, 2012-10-02 12:13 CEST (GLOBE NEWSWIRE) --
Pressemeddelelse
No. 7/2012
Resultater fra kliniske studier viser, at virkningsmekanismen for lixisenatid, som en GLP-1 agonist...
![Five abstracts on Ze](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Five abstracts on Zealand Pharma invented diabetes drug candidates, including Lyxumia® (lixisenatide), licensed to and developed by Sanofi, to be presented at the EASD 48th Annual Meeting
September 26, 2012 02:00 ET
|
Zealand Pharma A/S
Copenhagen, 2012-09-26 08:00 CEST (GLOBE NEWSWIRE) --
Press Release
No. 6/2012
-- One oral and two poster presentations of clinical data on Lyxumia®1 (lixisenatide), an investigational new...
![På det 48. årsmøde i](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
På det 48. årsmøde i EASD præsenteres fem abstracts på diabetes-lægemiddelkandidater, der er opfundet af Zealand Pharma, herunder Lyxumia® (lixisenatide), der er licenseret til og udvikles af Sanofi
September 26, 2012 02:00 ET
|
Zealand Pharma A/S
København, 2012-09-26 08:00 CEST (GLOBE NEWSWIRE) --
Pressemeddelelse
No. 6/2012
-- Én mundtlig og to poster-præsentationer af kliniske data på Lyxumia®1(lixisenatide), en ny GLP-1 agonist...
![Zealand Pharma A/S](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand Pharma A/S
September 17, 2012 04:17 ET
|
Zealand Pharma A/S
København, 2012-09-17 10:17 CEST (GLOBE NEWSWIRE) --
København, 17. september 2012 – I henhold til Værdipapirhandelslovens § 28a skal Zealand Pharma A/S indberette transaktioner, der omfatter...
![Zealand Pharma A/S](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand Pharma A/S
September 17, 2012 04:17 ET
|
Zealand Pharma A/S
Copenhagen, 2012-09-17 10:17 CEST (GLOBE NEWSWIRE) --
Copenhagen, 17 September 2012 – Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S shall announce transactions in...
![Zealand Pharma advan](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand Pharma advances ZP2929 into Phase I development for the treatment of Type 2 diabetes and/or obesity
September 13, 2012 03:30 ET
|
Zealand Pharma A/S
Copenhagen, 2012-09-13 09:30 CEST (GLOBE NEWSWIRE) --
Copenhagen, Denmark – 13 September 2012 – Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL), a Danish biotechnology company dedicated to...
![Zealand Pharma start](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand Pharma starter fase I-udvikling af ZP2929 inden for behandling af type 2-diabetes og/eller behandling af fedme
September 13, 2012 03:30 ET
|
Zealand Pharma A/S
København, 2012-09-13 09:30 CEST (GLOBE NEWSWIRE) --
København, 13. september 2012 - Zealand Pharma A/S (NASDAQ OMX København: ZEAL) meddeler at have doseret den første deltager i det...